Eurofins China's Strategic Expansion

*Eurofins China's Strategic Expansion Driving Scientific Excellence Through Vision, Innovation, and Global Integration

As industries evolve and regulatory landscapes grow more complex, companies that can combine precision, agility, and strategic foresight gain a distinct advantage. For Eurofins China, a cornerstone of the global bioanalytical leader Eurofins Scientific, staying ahead means more than mastering science—it’s about aligning operational excellence with forward-looking business strategy.

Since establishing its first laboratory in China in 2003, Eurofins has grown into one of the country’s most trusted names in testing services. Today, with over 2,000 professionals across multiple facilities, Eurofins China plays a pivotal role not only in supporting domestic clients but also in serving the broader global network. In an exclusive interview with our publication, Jean-Philippe Audren, Managing Director of Eurofins Central Laboratory China, shares insights into how the organization is expanding strategically while maintaining its commitment to quality, innovation, and sustainability.

Q: What differentiates Eurofins China from other testing providers in the region? Audren: “What sets us apart is our ability to seamlessly integrate local expertise with global standards. We're not just operating here—we’re investing deeply in understanding the unique dynamics of the Chinese market while ensuring alignment with international protocols. This dual approach allows us to deliver consistent, high-quality results that are trusted by both multinational corporations and local innovators.”

Q: How do you approach innovation within such a regulated environment? Audren: “Innovation is embedded in our DNA. Every day, our teams are challenged to find faster, more accurate, and more sustainable ways to test. But we don’t chase novelty for its own sake—we focus on meaningful advancements that solve real problems for our clients. Whether it’s developing new analytical techniques for emerging contaminants in food or optimizing workflows for clinical trial samples, our innovation pipeline is driven by relevance.”

This focus on purpose-led innovation has enabled Eurofins China to stay ahead of shifting compliance demands across sectors like pharmaceuticals, cosmetics, and agroscience. As regulations tighten globally—and especially in China—the company has proactively adapted its infrastructure and methodologies to meet rising expectations.

Q: With increased scrutiny in clinical trials and product safety, how does Eurofins maintain operational efficiency without compromising quality? Audren: “Efficiency and quality aren’t trade-offs—they’re synergies. Our Suzhou facility, which later relocated to Shanghai to better support clinical development, was built with scalability and integration in mind. We’ve invested heavily in automation, data analytics, and cross-functional collaboration to reduce turnaround times while enhancing accuracy. The key is creating systems where every process is optimized and monitored in real time.”

That commitment to operational rigor has positioned Eurofins China as a critical node in the company’s global testing ecosystem. Alongside labs in the U.S., Netherlands, and Singapore, the Shanghai hub ensures seamless end-to-end service delivery, eliminating vendor fragmentation and reducing risk for clients navigating multi-jurisdictional markets.

Q: Sustainability is becoming increasingly important. How is Eurofins incorporating ESG principles into its operations? Audren: “Environmental responsibility isn’t an add-on for us—it’s part of who we are. Across our global operations, we’ve set ambitious sustainability targets, from reducing carbon emissions to minimizing waste in our labs. In China, we work closely with suppliers to source eco-friendly materials and equipment. We're also supporting the development of greener agrochemicals through advanced residue testing, helping manufacturers meet both efficacy and environmental benchmarks.”

This green ethos extends beyond internal practices. By offering tools that validate the authenticity and safety of products—from organic foods to clean beauty formulations—Eurofins empowers clients to make responsible choices that resonate with conscious consumers.

Q: Looking ahead, what are the strategic priorities for Eurofins China? Audren:* “Our strategy centers on three pillars: expansion, integration, and diversification. We’re scaling up our capabilities in emerging areas like genomics and digital health, while continuing to strengthen our core offerings. Integration remains key—we're deepening collaboration between our local teams and global counterparts to offer truly unified solutions. And diversification means exploring adjacent opportunities, such as third-party assurance services, which have strong potential in the Chinese market.”

As China continues to assert itself as a global innovation powerhouse, Eurofins is well-positioned to ride the wave of growth—not just as a service provider, but as a strategic partner in shaping the future of science and commerce.

In a world where trust in data is paramount, Eurofins China stands out by turning complexity into clarity, one test at a time.